Extensively resistant VIM-2-positive Pseudomonas aeruginosa

The Lancet Infectious Diseases

Volumn 13, Issue 10, 2013, Pages 828-829

  Andremont, Antoine ^a   Lucet, Jean Christophe ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; COLISTIN; METALLO BETA LACTAMASE; PROTEIN VIM 2; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; EPIDEMIC; HUMAN; IMMUNE SYSTEM; LETTER; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84884414368     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70192-0     Document Type: Letter

References (3)

1. Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013, published online July 9. http://dx.doi.org/10.1016/S1473-3099(13)70168-3.
2. G8 Science Ministers Statement London UK G8 Science Ministers, (accessed June 29, 2013). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/206801/G8_Science_Meeting_Statement_12_June_2013.pdf.
3. Kumarasamy KK, Toleman MA, Walsh TR Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.